In the prospective study, there were 11, 21 and 2 vs 14, 15 and 3 patients who underwent BuCy, TBI-Cy and GIAC regimen in the continu. and intermit. group, respectively. For the retrospective study, clinical characteristics of patients are shown in Table 1. MESNA was purchased from Jiangsu Hengrui Medicine Co. (Lianyungang, Jiang Su Province, China). Both groups received the same daily dose of MESNA and about 150% of CTX daily dosage. In the intermit. group, 25% of MESNA dosage was injected at 0, 3, 6 and 9 h after the use of CTX. In the continu. group, 25% of MESNA dosage was injected 0 h before the use of CTX, while the remaining was continuously injected through IV for 24 h by using micro-infusion pump (25% of MESNA in 40 ml 0.9% sodium chloride lasting for 8 h, q8h) till 48 h after the last injection of CTX. Hydration, alkalinization and diuresis were used, and the volume of urine was kept 43 L/24 h.
The MESNA concentration in urine was measured by HPLC. The three observation points include: 0 h, immediately after CTX administration, and 12 h after the beginning of CTX.
Pearson χ 2 test was chosen for this case-control study as total case N was 440 and all theoretical frequencies were 45. Wilcoxon rank sum test, t-test and Cox regression analysis were used to analyze data. Expectation-Maximization algorithm was chosen to deal with missing data. All the statistical analyses were performed using SPSS17.0. (SPSS Inc., Standford, CA, USA).
In the prospective study, there was a statistically significant difference in the incidence of HC between the two groups in +30 and +60 days ( Table 2 ). In the prospective study, within +60 days, there were 11/32 cases of HC in the intermit. group (in grades I-IV 5, 2, 3 and 1 cases, respectively), while there were 2/34 cases in the continu. group (both are grade II). The mean time of HC occurrence was +12.7 days (−1 to +36 days) and +43.5 days (33 to +54 days) (P = 0.013) in patients of the intermit. and continu. groups, respectively. Based on the prospective study and ethical requirements where the protective effect of continuous IV of MESNA was proven to be better in the prevention of HC, we switched all HSCT patients to continu. group.
In the retrospective study, statistical significance of HC incidence rate exited between the two groups in +30 and +60 days (Table 2) . However, P = 0.063 to HC's grade within +60 days, 45/160 vs 30/234 cases of HC in the intermit. and continu. groups (in grades I-IV: 17, 18, 8 and 2 vs 17, 9, 4 and 0, respectively), there was no significant difference in the grade of HC within +60 days (P = 0.063). The mean time of HC occurrence was +19.5 days (−5 to +42 days) vs +27 days (−3 to +58 days), P = 0.037. There was no significant difference between mean input moisture, mean output moisture, mean 24-h urine volume in patients with and without HC in each group.
Within the first 60 days, in the prospective study, the mortality rate is 3.03% (2/66), with one death in each group; in the retrospective study, the mortality rate is 3.30% (13/394), including 6 cases in the intermit. and 7 cases in the continu. groups.
Cox regression analysis showed that, within +30 days, only HC occurrence was related with the method of MESNA administration (P = 0.001). Within +60d, the HC occurrence was related with the method of MESNA administration (P = 0.000) and GvHD (P = 0.001). Continuous MESNA injection is a protective factor within the first 30 and 60 days (odds ratio (OR) = 0.270, 95% confidence interval (CI) = 0.121-0.599) and (OR = 0.266, 95% CI = 0.135-0.524), respectively) while GvHD is a risk factor in +60 days (OR = 2.951, 95% CI = 1.598-5.451). Other factors such as age, sex, EBV and CMV were unrelated factors (each P40.05).
At three observation points (0 h, Immediately after CTX and 12 h after the beginning of CTX), the mean concentration of MESNA in the continu. group were as follows: 0 ± 0, 439.47 ± 34.34, 268.21 ± 24.51 μM in urine, and 0 ± 0, 56.62 ± 1.10, 37.06 ± 2.95 μM in serum. In the intermit. group, these were 0 ± 0, 409.99 ± 101.38, 0 ± 0 μM in urine and 0 ± 0, 40.86 ± 5.04, 5.33 ± 3.59 μM in serum.
The maximum concentration of acrolein in the bladder was achieved within 1-12 h after CTX (t 1/2 of CTX is 4-6 h); higher dose of CTX in HSCT leads to more acrolein and longer existence in bladder, so the traditional MESNA protocol could not provide efficient protection, [5] [6] [7] 9, 10 which is in accordance with our result. The full elimination of acrolein needs high concentration of MESNA at the minimal concentration of 10 μM. 11, 12 As the t 1/2 of MESNA is only 70 min, 3 it is better to prolong MESNA administration time than increasing dosage intermittently.
Markman et al. 13 recommends that continuous SC MESNA administration is a safe, practical and economic method of drug delivery; however, this method might increase the chances of infection, as well as requiring specific medical instrumentation. The EBMT Handbook (2012) also recommends other methods as follows: (1) Continuous infusion in 1 L of 0.9% saline over 12-24 h, beginning 4 h prior to the first dose of CTX and ending 12-24 h after the last CTX dose; or (2) Bolus injections, 20% of daily dose of CTX administered as a bolus 1 h before CTX and the remaining daily dose divided into bolus injections q2-3 h till 12-24 h after the last Cy administration. 1 The first method will increase fluid input, 1-2 L/day; the second method is too complicated and will increase the workload. In comparison, our continuous IV MESNA restricts the input fluid within 200 ml/24 h, which is a benefit for those requiring liquid input control.
The EBMT Handbook (2012) describes that positive BK viruria and HLA mismatching will increase the late HC rate; 1, 6, 10, 14 however, BK virus test began since September 2009 in Nanfang hospital, when the prospective study had been completed. For the same reason, none of the patients in the intermit. group has a BK virus result, so we do not use this index for statistics. Considering 34/234 in the continu. group and 2/160 in the intermit. group were haplo-HSCT (P = 0.000), the incidence of HC (7.26% within +30 days and 12.82% within +60 days) in the continu. group is quite low.
Our research proves that continuous IV of MESNA is an effective and safe method to prevent CTX-induced HC in HSCT. This improves the quality of life of patients and is worth applying on a large scale. Maintaining MESNA concentration in the urine is the key factor in prevention of HC in HSCT. 
